Episode Details

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company securing two US patents that significantly strengthen its PTSD treatment program. Tennyson explained that the patents cover two distinct chemical series, reinforcing the company’s intellectual property position and demonstrating that Solvonis is building “a novel chemistry platform and not just a single asset story.” He highlighted that having multiple chemically distinct approaches is critical in CNS drug discovery, increasing the likelihood of identifying compounds with the right balance of efficacy, safety, and translational potential. This strategy enhances optionality and flexibility as the program advances. The company has identified SVN-114 as its lead candidate and is now focused on progressing toward clinical development. Tennyson said Solvonis plans to pursue non-dilutive grant funding in both the UK and the US to support preclinical optimisation, with the goal of moving into IND-enabling studies and ultimately entering the clinic as efficiently as possible. Discussing the broader market, Tennyson pointed out that post-traumatic stress disorder affects around 20 million people across key markets, yet there are currently no approved treatments. He noted, “we see the granting of these patents as a validation of our science,” adding that the company aims to bring hope to patients and families impacted by PTSD. He also referenced growing interest from large pharmaceutical companies, signalling increasing commercial attention on the space. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #Solvonis #Biotech #PTSD #DrugDevelopment #PharmaNews #ClinicalTrials #CNS #HealthcareInnovation #Biopharma #Investing #IP #Patents #SVN114 #MentalHealth #LifeSciences